GBM is now subdivided into IDH wild-type (predominantly primary GBM, patients over 55 years of age, poor prognosis) and IDH-mutant entities (predominantly secondary GBM, younger patients, favorable prognosis). Here, IDH1 is linked to glioblastoma.